# A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects

> **NCT06562088** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Healthy Adult Subject

## Interventions

- **DRUG:** HDM1002 and rifampicin
- **DRUG:** HDM1002 and itraconazole

## Key facts

- **NCT ID:** NCT06562088
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06562088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06562088, "A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06562088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*